1. Fixed-Ratio Combination Therapy in T2DM

3. Program Overview

4. Consequences of Delaying Intensification of Therapy in T2DM

5. Therapeutic Inertia

6. Likelihood of Achieving Glycemic Control With Basal Insulin

7. Healthcare System Barriers to Advancing Therapy

8. Intensification of Insulin Therapy With FRCs

9. Benefits of Basal Insulin/GLP-1 RA FRCs

10. Practical Benefits of Basal Insulin/GLP-1 RA FRCs

11. Basal Insulin/GLP-1 RA FRC Agents

12. Reduction in Risk for Side Effects

13. Impact of T2DM Duration on Response to IGlarLixi v Glargine

14. Mean Daily Dose of Basal Insulin Significantly Lower With FRC Therapy

15. The Importance of Individualizing Therapy

16. IDegLira vs Basal-Bolus Insulin

17. FRC vs Prandial Insulin

18. Carbohydrate Counting

19. Use of FRCs in Clinical Practice

20. Use of FRCs in Clinical Practice (cont)

21. Patients Who Could Benefit From FRCs

22. Practical Considerations for Using FRCs

23. Using a Basal Insulin/GLP-1 RA FRC - IGlarLixi

24. Using a Basal Insulin/GLP-1 RA FRC - IDegLira

25. Summary

26. Abbreviations

27. Abbreviations (cont)